Parabolic Drugs Financial Statements

Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar Mar-2018 Mar-2017 Mar-2016 Mar-2015
Growth matrix (%)        
Revenue growth (2.30) (2.50) (67) (47)
Op profit growth (64) (85) 287 (4.40)
EBIT growth (50) (75) 147 9.22
Net profit growth (47) (78) 27.70 184
Profitability ratios (%)        
OPM (23) (62) (399) (34)
EBIT margin (65) (126) (486) (65)
Net profit margin (79) (144) (632) (164)
RoCE (25) (36) (69) (17)
RoNW 1.74 3.63 27.20 685
RoA (7.70) (10) (22) (10)
Per share ratios ()        
EPS -- -- -- --
Dividend per share -- -- -- --
Cash EPS (15) (26) (89) (73)
Book value per share (138) (129) (111) (33)
Valuation ratios        
P/E -- -- -- --
P/CEPS (0.50) (0.30) (0.10) (0.10)
P/B (0.10) (0.10) -- (0.30)
EV/EBIDTA (80) (25) (3.30) (13)
Payout (%)        
Dividend payout -- -- -- --
Tax payout 3.15 2.90 0.92 52.10
Liquidity ratios        
Debtor days 239 335 400 195
Inventory days 77.70 135 846 538
Creditor days (378) (299) (93) (171)
Leverage ratios        
Interest coverage 5.68 8.72 3.47 1.53
Net debt / equity (1.10) (1.20) (1.40) (4.70)
Net debt / op. profit (58) (21) (3.20) (12)
Cost breakup ()        
Material costs (87) (124) (429) (110)
Employee costs (13) (12) (14) (7.50)
Other costs (23) (26) (56) (16)
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar( In .Cr) Mar-2018 Mar-2017 Mar-2016 Mar-2015
Revenue 73.20 74.90 76.80 232
yoy growth (%) (2.30) (2.50) (67) (47)
Raw materials (64) (93) (330) (256)
As % of sales 87.30 124 429 110
Employee costs (9.80) (9) (11) (17)
As % of sales 13.40 12.10 14.20 7.52
Other costs (17) (20) (43) (38)
As % of sales 22.60 26.20 56 16.20
Operating profit (17) (47) (307) (79)
OPM (23) (62) (399) (34)
Depreciation (35) (54) (67) (73)
Interest expense (8.40) (11) (108) (99)
Other income 4.16 6.20 0.33 1.24
Profit before tax (56) (105) (481) (250)
Taxes (1.80) (3.10) (4.40) (130)
Tax rate 3.15 2.90 0.92 52.10
Minorities and other -- -- -- --
Adj. profit (58) (108) (486) (380)
Exceptional items -- -- -- --
Net profit (58) (108) (486) (380)
yoy growth (%) (47) (78) 27.70 184
NPM (79) (144) (632) (164)
Switch to
Tabular Data
Graph
Y/e 31 Mar ( In .Cr) Mar-2018 Mar-2017 Mar-2016 Mar-2015
Profit before tax (56) (105) (481) (250)
Depreciation (35) (54) (67) (73)
Tax paid (1.80) (3.10) (4.40) (130)
Working capital (666) (611) (559) (78)
Other operating items -- -- -- --
Operating cashflow (758) (773) (1,112) (531)
Capital expenditure 295 262 101 87.60
Free cash flow (463) (511) (1,011) (444)
Equity raised (543) (385) (31) 229
Investments (2.40) 0.11 0.06 0.05
Debt financing/disposal 677 594 263 176
Dividends paid -- -- -- --
Other items -- -- -- --
Net in cash (331) (301) (779) (39)
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar ( In .Cr) Mar-2018 Mar-2017 Mar-2016 Mar-2015
Equity capital 87.90 87.90 87.90 87.90
Preference capital -- -- -- --
Reserves (943) (886) (778) (292)
Net worth (855) (798) (690) (204)
Minority interest
Debt 983 978 971 957
Deferred tax liabilities (net) 34.70 32.90 29.90 25.50
Total liabilities 162 214 312 779
Fixed assets 333 355 378 402
Intangible assets
Investments 0.14 0.13 0.13 0.12
Deferred tax asset (net) 0.92 0.92 0.92 0.92
Net working capital (172) (144) (68) 373
Inventories 15.90 15.30 40.40 316
Inventory Days 79.20 74.30 192 497
Sundry debtors 28.80 67.10 70.20 98.20
Debtor days 144 327 334 154
Other current assets 30.30 45.40 79.70 124
Sundry creditors (81) (106) (93) (102)
Creditor days 404 516 443 161
Other current liabilities (166) (165) (165) (63)
Cash 0.87 0.64 0.73 3.20
Total assets 162 214 312 779
Switch to
Consolidated
Standalone


Particulars ( Rupees In Crores.) Mar-2018 Mar-2017 Mar-2016 Mar-2015 Mar-2014
Gross Sales 72.40 70.30 84.30 240 447
Excise Duty -- -- 8.88 11.20 16.30
Net Sales 72.40 70.30 75.50 229 430
Other Operating Income 0.81 4.60 1.70 4.24 20.30
Other Income 4.16 6.19 -- -- 27
Total Income 77.30 81.10 77.20 233 478
Total Expenditure ** 89.80 122 384 311 521
PBIDT (12) (41) (306) (78) (43)
Interest 8.36 10.80 108 99 83.70
PBDT (21) (51) (414) (177) (127)
Depreciation 34.50 53.70 67.20 73.20 68.30
Minority Interest Before NP -- -- -- -- --
Tax 1.76 3.06 4.43 130 (61)
Deferred Tax -- -- -- -- --
Reported Profit After Tax (57) (108) (486) (380) (134)
Minority Interest After NP -- -- -- -- --
Net Profit after Minority Interest (57) (108) (486) (380) (134)
Extra-ordinary Items -- -- -- -- 27
Adjusted Profit After Extra-ordinary item (57) (108) (486) (380) (161)
EPS (Unit Curr.) (9.30) (17) (78) (61) (22)
Book Value (Unit Curr.) -- -- -- -- --
Dividend (%) -- -- -- -- --
Equity 61.90 61.90 61.90 61.90 61.90
Public Shareholding (Number) -- 38,496,287 37,974,587 37,974,587 38,182,936
Public Shareholding (%) -- 62.20 61.40 61.40 61.70
Pledged/Encumbered - No. of Shares -- 22,619,927 22,619,927 22,619,927 22,372,320
Pledged/Encumbered - % in Total Promoters Holding -- 96.70 94.60 94.60 94.40
Pledged/Encumbered - % in Total Equity -- 36.60 36.60 36.60 36.20
Non Encumbered - No. of Shares -- 775,800 1,297,500 1,297,500 1,336,759
Non Encumbered - % in Total Promoters Holding -- 3.32 5.42 5.42 5.64
Non Encumbered - % in Total Equity -- 1.25 2.09 2.09 2.16
PBIDTM(%) (17) (58) (406) (34) (10)
PBDTM(%) (29) (73) (549) (77) (29)
PATM(%) (79) (154) (644) (166) (31)